Patients with estrogen receptor (ER)-positive disease have a long-term risk for fatal breast cancer, but he biological factors are unknown. To investigate whether high intratumor heterogeneity of ER is associated with this increased risk, users of the SciLifeLab Tissue Profiling facility studied the tumors of 1780 postmenopausal women and the patients’ survival rate. The results show that patients with high intratumor heterogeneity of ER had an increased long-term risk of fatal breast cancer, suggesting that this factor could be used as a prognosticator with potential to change clinical management. The study was published in JNCI.
Read the full paper in JNCI
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.